An interventional study of Midazolam oral solution and Placebo in Preoperative, Sleep Disturbance and Anxiety, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing midazolam in Pain, Postoperative — 3 open to participants now, 3 under way, none of them phase 3. Midazolam · Pain, Postoperative.
Among the 13 studies testing midazolam in Pain, Postoperative, this one has the largest planned enrollment, is the only one that started in 2024, is one of 4 with no phase, and was the 12th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →3 of the 13 studies testing midazolam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
Erzurum City Hospital · Sites in Turkey
Ages 3–10
Assiut University
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
Midazolam: first FDA approval 1985 (VERSED), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 13 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 217 studies on the registry; 111 are open to participants now.
Sixth Affiliated Hospital, Sun Yat-sen University has 5 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
1 of the studies testing midazolam in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07622641Erzurum City HospitalTiming Of Midazolam İn Children Undergoing Adenotonsillectomy: Effects On Stress, Cortisol, And Recovery | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing midazolam in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Previous studies have indicated a high incidence of sleep disturbances and anxiety symptoms in individuals with colorectal cancers prior to undergoing surgery, leading to worsened postoperative pain, slower recovery, and higher risk of chronic pain. The enhancement of sleep quality is intricately linked to reducing stress. Preoperative drugs that combine hypnosis and anti-anxiety have not been studied in colorectal cancer patients. Midazolam oral solution is safe and effective for short-term hypnotic and anti-anxiety effects in clinical preoperative settings. In the current randomized controlled clinical trial, 280 patients experiencing sleep disturbance or anxiety prior to colorectal cancer surgery will receive midazolam solution to assess its potential efficacy in reducing postoperative pain, expediting recovery, and decreasing the likelihood of chronic pain. Additionally, the study aims to explore the potential connections between midazolam administration and reductions in stress and inflammation.
Preoperative sleep disturbance and anxiety worsen postoperative pain for patients undergoing surgeries. Research indicates that a significant proportion of patients, ranging from 8.8% to 79.1%, experience disturbances in sleep or anxiety prior to surgery. These preoperative issues have been shown to have lasting and intricate effects on postoperative pain, fatigue, and depression. Therefore, it is imperative for clinical doctors to promptly identify preoperative sleep disturbances and anxiety in order to offer appropriate support to patients.
Colorectal cancer is the fifth leading cause of death in China, with nearly 40% of patients experiencing insomnia before surgery, consistent with our previous studies. A case-control study demonstrated a protective association between improved sleep quality and relief of postoperative pain in colorectal cancers. Furthermore, individuals undergoing laparoscopic colorectal surgery showed a higher likelihood of experiencing visceral pain compared to somatic pain. Acute visceral pain has the potential to progress into chronic visceral pain, resulting in behavioral manifestations such as anxiety, fear, and depression, which may persist and exacerbate into enduring chronic pain, ultimately impacting the individual's quality of life. Currently, studies have shown that disturbed preoperative sleep has become a significant predictor of both acute and chronic postoperative pain. Therefore, finding effective interventions to promote preoperative sleep is a continuing consideration for clinicians.
Pharmacological intervention is the primary approach for preoperative sleep disturbances or anxiety. Finding appropriate drug is a challenge that needs to be solved in the clinical practice. There is currently a lack of evidence-based medical guidelines regarding pharmacologic interventions for preoperative sleep disturbances and anxiety. Research has indicated that zolpidem can enhance sleep quality in patients prior to surgery, decrease the need for analgesics during the procedure, and alleviate postoperative pain. Nevertheless, there is a demand for agents that possess both short-term hypnotic and anxiolytic properties, whereas zolpidem solely exhibits hypnotic effects. Midazolam, a short-acting benzodiazepine, is often used before anesthesia for its short-term hypnotic and anxiolytic effects. Studies have found that midazolam oral solution is safe and effective for short-term use in clinical pre-surgical settings. There are no studies on using oral midazolam solution to improve sleep and reduce anxiety in colorectal cancer patients before surgery. Our previous research found that a dose of 7.2mg can effectively induce sleep with minimal side effects in 50% patients before surgery.
In summary, the present study intends to carry out a prospective,randomized,double-blind,placebo-controlled clinical study to investigate the hypothesis that preoperative oral midazolam solution could reduce acute postoperative pain, promote early recovery, and reduce the risk of chronic pain in patients with poor sleep or anxiety before colorectal cancer surgery. It is postulated that the potential benefits of preoperative oral midazolam solution may be attributed to decreased stress levels, and lowered inflammation markers.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
This study's planned enrollment of 280 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 217 studies on the registry; 111 are open to participants now.
Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention drug is midazolam oral solution at a dose of 7-10mg. The starting dosage is 7mg, with subsequent individual increases of 1mg up to a maximum dose of 10mg if patients do not achieve sleep within 30 minutes of administration. The individual dose wil be consistently maintained at the corresponding level every night until the surgery.
Drug: Midazolam oral solution
Placebo is a solution of midazolam oral solution that looks, tastes, and appears the same as the intervention drug, similar to the experimental group increment method.
Other: Placebo
Each individual administers the midazolam oral solution nightly from enrollment to the surgry.
Also known as: Midazolam oral solution, YICHANG HUMANWELL PHARMACEUTICAL
Each individual administers placebo solution nightly from enrollment to the surgry.
Incidence of moderate to severe pain on the first postoperative day
NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Moderate to severe pain: Mean NRS pain score ≥4; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).
Time frame: on the first postoperative day for Acute Postoperative Pain
Mean NRS pain score
NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).
Time frame: on the first postoperative day for Acute Postoperative Pain
Mean NRS pain score
NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).
Time frame: on the second postoperative day for Acute Postoperative Pain
Mean NRS pain score
NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).
Time frame: on the third postoperative day for Acute Postoperative Pain
Incidence of moderate to severe pain
NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Moderate to severe pain: Mean NRS pain score ≥4; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).
Time frame: on the second postoperative day for Acute Postoperative Pain
Incidence of moderate to severe pain
NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Moderate to severe pain: Mean NRS pain score ≥4; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).
Time frame: on the third postoperative day for Acute Postoperative Pain
The number of times analgesics being added
The number of additional postoperative analgesics, by Patient-Controlled Analgesia or prescribed by doctors
Time frame: on the first postoperative day for Acute Postoperative Pain
The number of times analgesics being added
The number of additional postoperative analgesics, by Patient-Controlled Analgesia or prescribed by doctors
Time frame: on the second postoperative day for Acute Postoperative Pain
The number of times analgesics being added
The number of additional postoperative analgesics, by Patient-Controlled Analgesia or prescribed by doctors
Time frame: on the third postoperative day for Acute Postoperative Pain
Total scores of the questionnaire of 15-item Quality of Recovery scale
QoR-15: 15-item Quality of Recovery scale; QoR-15 is a patient-reported measure, and is used to assess global recovery quality after surgery physiologically and psychologically. QoR-15 contents 15 items, which item is constructed by an 11-point numerical rating scale (for positive items, 0="none of the time"to 10="all of the time"; for negative items the scoring are reversed). The total scores are ranging from 0(extremely poor QoR) to 150 (excellent QoR).
Time frame: on the first postoperative day
Total scores of the questionnaire of 15-item Quality of Recovery scale
QoR-15: 15-item Quality of Recovery scale; QoR-15 is a patient-reported measure, and is used to assess global recovery quality after surgery physiologically and psychologically. QoR-15 contents 15 items, which item is constructed by an 11-point numerical rating scale (for positive items, 0="none of the time"to 10="all of the time"; for negative items the scoring are reversed). The total scores are ranging from 0(extremely poor QoR) to 150 (excellent QoR).
Time frame: on the second postoperative day
Total scores of the questionnaire of 15-item Quality of Recovery scale
QoR-15: 15-item Quality of Recovery scale; QoR-15 is a patient-reported measure, and is used to assess global recovery quality after surgery physiologically and psychologically. QoR-15 contents 15 items, which item is constructed by an 11-point numerical rating scale (for positive items, 0="none of the time"to 10="all of the time"; for negative items the scoring are reversed). The total scores are ranging from 0(extremely poor QoR) to 150 (excellent QoR).
Time frame: on the third postoperative day
Requirement for propofol when induction of general anesthesia
Propofol is titrated for the purpose of achieving general anesthesia prior to colorectal cancer resection. Upon reaching the titration endpoint, indicated by an OAAS sedation score of 0, the dosage of propofol administered (in mg/kg) is documented. OAAS:Observer's Assessment Alertness/Sedation scale
Time frame: on the day of colorectal cancer resection and general anesthesia
Incidence of post-anesthesia care unit (PACU) stays longer than 1 hour
Following the surgical procedure, the patient is relocated to the Post-Anesthesia Care Unit (PACU). Patients may be transferred to the general ward once their postoperative resuscitation meets established standards. Incidence of PACU stays longer than 1 hour is recorded.
Time frame: on the day of colorectal cancer resection and general anesthesia
The amount of additional analgesics in PACU
The quantity of supplementary analgesic medications administered in PACU
Time frame: on the day of colorectal cancer resection and general anesthesia
Incidence of fever in the first 72 hours after surgery
The incidence of axillary temperatures above 38℃ within 72 hours post-surgery is recorded.
Time frame: In the third postoperative day
Length of hospital stay after surgery
Length of hospital stay after surgery:hospital stay time (days) from operation completion to actual hospital discharge
Time frame: Days from operation completion to actual hospital discharge (expected 7 days after surgery)
The financial burden in the hospital after surgery
Medical costs from operation completion to actual hospital discharge
Time frame: Days from operation completion to actual hospital discharge (expected 7 days after surgery)
Incidence of unplanned reoperations within 30 Days after Surgery
Incidence of unplanned reoperations within 30 Days after Surgery
Time frame: within 30 days after surgery
Incidence of unplanned admissions within 30 Days after Surgery
Incidence of unplanned admissions within 30 Days after Surgery
Time frame: within 30 days after surgery
Total score of The Brief Pain Inventory at the 30th day after surgery
The Brief Pain Inventory: to survey postoperative chronic pain after surgery
Time frame: at the 30th day after surgery for chronic Postoperative Pain
Total score of The Brief Pain Inventory at the 90th day after surgery
The Brief Pain Inventory: to survey postoperative chronic pain after surgery
Time frame: at the 90th day after surgery for chronic Postoperative Pain
Total score of SF-36 at the 30th day after surgery
SF-36: The short form (SF)-36 is an instrument to survey postoperative health status.
Time frame: at the 30th day after surgery for postoperative health status
Total score of SF-36 at the 90th day after surgery
SF-36: The short form (SF)-36 is an instrument to survey postoperative health status.
Time frame: at the 90th day after surgery for postoperative health status
Number of patients still taking pain medication on day 30 after surgery
Number of patients still taking pain medication on day 30 after surgery
Time frame: on the 30th day after surgery
Number of patients still taking pain medication on day 90 after surgery
Number of patients still taking pain medication on day 90 after surgery
Time frame: on the 90th day after surgery
Incidence of post-traumatic stress disorder (PTSD) at 30 days post-surgery
The prevalence of post-traumatic stress disorder as measured by the PC-PTSD scale at 30 days following surgical procedures. PC- PTSD:Primary Care Post traumatic Stress Disorder
Time frame: on the 30th day after surgery
Incidence of post-traumatic stress disorder (PTSD) at 90 days post-surgery
The prevalence of post-traumatic stress disorder as measured by the PC-PTSD scale at 90 days following surgical procedures. PC- PTSD:Primary Care Post traumatic Stress Disorder
Time frame: on the 90th day after surgery
The ratio of neutrophils to lymphocytes in peripheral blood on the first day after surgery
The ratio of neutrophils to lymphocytes in peripheral blood on the first day after surgery
Time frame: on the first day after surgery
The ratio of neutrophils to lymphocytes in peripheral blood on the third day after surgery
The ratio of neutrophils to lymphocytes in peripheral blood on the third day after surgery
Time frame: on the third day after surgery
The ratio of platelets to lymphocytes in peripheral blood on the first day after surgery
The ratio of platelets to lymphocytes in peripheral blood on the first day after surgery
Time frame: on the first day after surgery
The ratio of platelets to lymphocytes in peripheral blood on the third day after surgery
The ratio of platelets to lymphocytes in peripheral blood on the third day after surgery
Time frame: on the third day after surgery
C-reactive protein levels in peripheral blood on the first day after surgery
C-reactive protein levels in peripheral blood on the first day after surgery
Time frame: on the first day after surgery
C-reactive protein levels in peripheral blood on the third day after surgery
C-reactive protein levels in peripheral blood on the third day after surgery
Time frame: on the third day after surgery
Opioid consumption in milligrams of intravenous morphine equivalents within three days after surgery
Opioid consumption in milligrams of intravenous morphine equivalents within three days after surgery
Time frame: within three days after surgery
Opioid consumption in milligrams of intravenous or oral morphine equivalents within 30 days after surgery
Opioid consumption in milligrams of intravenous or oral morphine equivalents within 30 days after surgery
Time frame: within 30 days after surgery
Opioid consumption in milligrams of intravenous or oral morphine equivalents within 90 days after surgery
Opioid consumption in milligrams of intravenous or oral morphine equivalents within 90 days after surgery
Time frame: within 90 days after surgery
Incidence of nausea (requiring treatment) and vomiting within three days after surgery
Incidence of nausea (requiring treatment) and vomiting within three days after surgery
Time frame: within three days after surgery
Incidence of patients mobilising on the first day after surgery
Incidence of patients mobilising on the first day after surgery
Time frame: on the first day after surgery
time until first flatus after surgery in days
time until first flatus after surgery in days
Time frame: time until first flatus after surgery in days (generally, within the three days after surgery )
Incidence of complications related to surgery within 30 days after surgery
Incidence of complications related to surgery within 30 days after surgery \[ complication grade according to Clavien-Dindo(No complications,Grade I-II,Grade IIIa + IIIb,Grade IV,Grade V)\]
Time frame: within 30 days after surgery
Salivary cortisol
preoperative Salivary cortisol
Time frame: Days from admission to the day of surgery (expected 5 days before surgery)
Cytokine group
Peripheral blood being collected before surgery
Time frame: on the surgery day (before general anesthesia and surgery)
Endocannabinoids
Peripheral blood being collected before surgery
Time frame: on the surgery day (before general anesthesia and surgery)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 15 months is above that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midazolam
Sixth Affiliated Hospital, Sun Yat-sen University →